Stockreport

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Billion [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF The deal bolsters the U.K. pharmaceutical company's vaccine portfolio at a time when bird-flu concerns are boosting demand. Vaccines accounted for roughly a third of GS [Read more]